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Introduction: Rituximab is an emerging treatment for autoimmune hemolytic anemia. We report the case of a patient
with a five-year complete hematologic response to a third course of treatment with rituximab. Cases of response to
rituximab re-treatments have been reported, but none to our knowledge that failed multiple prior treatments and
achieved as durable a response.
Case presentation: A 45-year-old Hispanic man presented at age 26 with darkening urine and cold intolerance.
His blood tests revealed elevated lactic dehydrogenase and bilirubin, a hemoglobin level of 7.4g/dL, and a positive
Coombs test for complement C3 and immunoglobulin G antibody. A diagnosis of autoimmune hemolytic anemia
was made. After failing multiple therapies including prednisone, splenectomy, immunoglobulin, cyclosporine, danocrine
and azathioprine, our patient was treated with a four-week course of rituximab at a dose of 375mg/m2 weekly, 10 years
following initial presentation. He achieved a rapid and complete hematologic response that lasted 25 months.
Re-treatment with the same course of rituximab prompted a second response that lasted 18 months. A third
re-treatment has achieved an ongoing five-year complete hematologic response.
Conclusions: This is an unusual case of a durable five-year remission of autoimmune hemolytic anemia with rituximab
re-treatment following relapse after two prior courses of rituximab and despite the persistence of immunoglobulin G
and complement-coated red blood cells. No mechanistic explanations for improved response to rituximab
re-treatment in autoimmune hemolytic anemia have been reported in the literature. Future studies of rituximab or
other B cell-targeting antibodies in the treatment of autoimmune hemolytic anemia should explore autoantibody
immunoglobulin G subclass switching and alterations in complement inhibitory proteins on red blood cell membranes
as potential correlates of hematologic response.
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Autoimmune hemolytic anemia (AIHA) is characterized
by B cell production of autoantibodies that bind to red
blood cell surface antigens and initiate red blood cell
destruction. Treatments aim to reduce autoantibody
production or immune-mediated clearance of opsonized
red blood cells and include glucocorticoids and other* Correspondence: khege@celgene.com
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cytotoxic agents, monoclonal antibodies, and splenectomy.
Rituximab, an immunoglobulin G1 (IgG1) kappa chimeric
monoclonal antibody directed against the CD20 antigen
expressed on B cells, has established efficacy in the treat-
ment of refractory AIHA. A 2009 Belgian retrospective
study yielded a 79 percent hematologic response rate in 53
subjects with refractory AIHA treated with rituximab [1],
and a 2009 Spanish retrospective study similarly demon-
strated a 77 percent response rate in 36 subjects with
AIHA [2]. Achievement of a negative direct antiglobulinntral Ltd. This is an Open Access article distributed under the terms of the
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been shown to be a predictor of more durable responses
[2]. The Belgian study noted some cases of re-treatment re-
sponses to rituximab that lasted longer than the initial
treatment [1].
Here we present the case of a patient with an ongoing
five-year complete hematologic response to a third
course of rituximab for the treatment of multiply re-
lapsed AIHA following two prior rituximab responses of
shorter duration. Our patient’s hemoglobin and hematocrit
levels remain in the normal range despite a persistently
positive Coombs test. This unusual case supports the utility
of rituximab re-treatment and prompts further investiga-
tion into the mechanism of action of rituximab and its ef-
fect on the pathogenicity of red blood cell autoantibody
and complement-mediated hemolysis.
Case presentation
Our patient is a 45-year-old Hispanic man first diag-
nosed with AIHA at age 26 in January 1995. He initially
presented after noticing darkening of his urine and cold
intolerance in the month preceding his diagnosis. La-
boratory tests revealed elevated lactic dehydrogenase
(LDH) and bilirubin, a hemoglobin level of 7.4g/dL, and
a Coombs test positive for complement (C3) and im-
munoglobulin G (IgG) antibody. Further evaluation ruled
out an underlying lymphoma, other malignancy, or an as-
sociated systemic autoimmune disorder, and a diagnosis
of AIHA was made. His anemia initially responded to
prednisone at a dose of 80mg daily, but multiple attempts
to taper and discontinue prednisone resulted in recurrent
hemolysis and anemia. Additional therapies included
pulse dexamethasone treatment from January to April
1996 and a splenectomy in August 1996. Hemolysis and
anemia persisted following the splenectomy, and he was
subsequently treated with various combinations of pred-
nisone, intravenous immunoglobulin, danocrine, cyclo-
sporine, and azathioprine. His treatment course was
complicated by cryptococcal meningitis in April of 1997
and refractory cutaneous warts secondary to chronic im-
munosuppression. In addition, he had an acute myocardial
infarction in October 2001 at the age of 32.
Following initial case reports of hematologic response
in refractory AIHA treated with rituximab [3,4], our pa-
tient received his first treatment with a four-week course
of rituximab at a dose of 375mg/m2 weekly in February,
2005. Pretreatment laboratory tests showed a hemoglobin
level of 12.3g/dL, reticulocyte count of 290×109/L, and
persistent positive Coombs test with IgG 3+ and C3 1+.
He achieved a rapid and complete hematologic response
with normalization of his hemoglobin and reticulocyte
count for the first time in his history. By June 2005, his
hemoglobin and reticulocyte count were in the normal
range at 14.7g/dL and 149×109/L, respectively. Chronicimmune suppressive therapy with prednisone, danocrine
and azathioprine was tapered and stopped over the next
four months. This first response to rituximab lasted 25
months. Recurrent hemolysis developed in March 2007,
manifested by a hemoglobin count of 13.0g/dL and reticu-
locyte count of 206×109/L, and prompted re-treatment
with another four-week course of rituximab. Our patient
achieved a second complete hematologic response with a
rise in hemoglobin level to 16.4g/dL and decrease in re-
ticulocyte count to 105×109/L. Hemolysis again recurred
in September 2008 with a drop in his hemoglobin level to
11.3g/dL after an 18-month duration of response. He was
re-treated with a third four-week course of rituximab at
the same dose and schedule. Since this last course of rituxi-
mab he has maintained an ongoing five-year complete
hematologic response with hemoglobin levels within the
normal range through September 2013.
This third hematologic response (ongoing at five years)
is more than twice the duration of either of his previous
responses (25 and 18 months, respectively) and persists
despite the continued presence of IgG antibodies and
complement on his red blood cells, detected by a persist-
ently positive Coombs test (IgG 4+, C3 1+). He has been
off all immunosuppressive therapy other than the three
courses of rituximab since 2005. Absolute lymphocyte
count and B and T cells subsets in his blood, as mea-
sured by flow cytometry, are within normal limits. Main-
tenance fluconazole therapy for cryptococcal meningitis
was stopped in 2005 without recurrence of meningitis,
and his refractory cutaneous warts have completely re-
solved without specific therapy. He has suffered no add-
itional cardiac ischemic episodes. A longitudinal summary
of his hemoglobin and reticulocyte counts as well as rituxi-
mab administration is presented in Figure 1.
Discussion
This case report describes a durable five-year complete
hematologic response to rituximab in a subject with re-
fractory AIHA despite relapse following two prior ri-
tuximab treatments and the persistence of a positive
Coombs test. This case raises two related questions. First,
why are the autoantibodies and complement persistently
detected on the patient’s red blood cells no longer caus-
ing hemolysis, and what mechanistic role might rituxi-
mab have played in this transition? Second, why did a
third course of treatment with rituximab result in a last-
ing hematologic remission, when the same treatment
regimen resulted in much shorter response durations on
two previous occasions? Here we conduct an exploration
of these questions based on literature review and retro-
spective analysis of this case.
Several factors influence the pathogenicity of red blood
cell-bound autoantibodies and associated induction of





















































Figure 1 Hemoglobin levels and reticulocyte counts from 2003 to 2013. *Method of measuring reticulocytes changed in December, 2007.
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complement-activating efficiency, affinity and amount of
galactose on the (crystallizable fragment (Fc) carbohy-
drate), quantity of cell-bound antibodies, and activity of
the complement-mediated and phagocytic clearance sys-
tems [5]. Of these factors, rituximab is most likely to
affect red blood cell autoantibody characteristics, due to
its mechanism of action of selective B cell depletion [6].
One possible explanation for the loss of autoantibody
pathogenicity is a change in IgG subclass. The human
IgG subclasses IgG1, IgG2, IgG3, and IgG4 have identi-
cal variable regions but differ in the heavy chain. The
pathogenic potential of autoantibodies is directly related
to the binding properties of the heavy chain Fc region,
and variation in pathogenicity and hemolysis induction
between subclasses has been shown in mice [7]. In
humans, IgG4 autoantibodies are known to be poorly
pathogenic, lacking the ability to activate complement
and trigger macrophage phagocytosis. IgG2 autoanti-
bodies activate complement poorly and only react with
macrophages if the Fc receptor is of a particular allotype
[5]. It is therefore plausible that a switch from a highly
pathogenic subclass, IgG1 or IgG3, to a poorly patho-
genic subclass, IgG2 or IgG4, could be responsible for
the termination of our patient’s hemolysis, despite per-
sistence of red blood cell-bound autoantibodies. Further
exploration is warranted to determine if rituximab re-
sponse in AIHA is associated with IgG subclass switch-
ing. In future studies, the relative levels of different IgG
subclasses on red blood cells before and after rituximab
treatment might be tested by nephelometry or another
known method.
Several researchers have suggested the immune com-
plex decoy hypothesis as an important component of themechanism of action of rituximab and an explanation
for its rapid effect in inhibiting hemolysis [8]. The com-
plex decoy hypothesis asserts that the immune com-
plexes formed by rituximab bound to B cells serve as
alternative substrates for both circulating monocytes and
fixed tissue macrophages, thereby distracting these ef-
fector cells from the destruction of IgG and C3-opsonized
red blood cells [8]. Inhibition of hemolysis associated with
this complex decoy hypothesis is postulated to be transi-
tory in nature, and though it may explain our patient’s
rapid response to rituximab after each treatment, it cannot
explain the ongoing five-year hematologic response. This
hematologic remission persists in the presence of normal
circulating B and T lymphocyte counts (absolute lympho-
cyte count 1.7×109/L, CD3+ T cells 935×106/L, CD19+ B
cells 629×106/L) and long after the clearance of rituximab
and rituximab-bound B cells from his system.
Complement inhibitory proteins such as CD55 and
CD59 that protect from uncontrolled complement-
mediated red blood cell lysis may also play a role in
our patient’s hematologic remissions. CD55 and CD59
are glycosylphosphatidylinositol-anchored, type I cell sur-
face proteins that inhibit formation of the C3 convertases
and prevent the terminal polymerization of the mem-
brane attack complex, respectively [9]. A 2009 study by
Barros et al. demonstrated low expression of CD59 in
warm autoimmune hemolytic anemia, while CD55 ex-
pression was unchanged between AIHA patients and
healthy individuals [10]. Barros et al. conclude that com-
plement inhibitory proteins may play an important role
in protecting red blood cells from destruction by comple-
ment [10]. This prompts consideration of the possibility
that upregulation of complement inhibitory proteins, such
as CD55 and CD59, from low to normal levels might
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of action of rituximab in treating AIHA. As these comple-
ment inhibitory proteins are involved in regulation of B cell
destruction by rituximab, interplay between the inhibitory
proteins, rituximab, and the C3-opsonized red blood cells
might contribute to the hematologic response observed
with rituximab treatment in AIHA. A 2001 study by Weng
and Levy found no change in CD55 or CD59 levels mea-
sured by flow cytometry in patients with non-Hodgkin
lymphoma following rituximab treatment [9], but this topic
warrants further exploration, specifically in AIHA, by test-
ing CD55 and CD59 levels on red blood cells by flow cy-
tometry before and after rituximab treatment.
It remains uncertain why our patient developed recur-
rent hemolysis after two prior rituximab treatments,
with response durations of 25 and 18 months, respect-
ively, but is experiencing a lasting response, ongoing at
five years, to the third course of treatment. Previous
cases of increased response durations following retreat-
ment of AIHA with rituximab have been observed [1],
but to the best of our knowledge, five-year hematologic
remissions following multiple prior relapses have not
previously been reported.Conclusions
This report describes an unusual case of a durable five-
year remission of AIHA with rituximab retreatment fol-
lowing relapse after two prior courses of rituximab and
despite the persistence of IgG and complement-coated
red blood cells. No mechanistic explanations for im-
proved response to rituximab retreatment in AIHA have
been reported in the literature. Future studies of rituxi-
mab or other B cell-targeting antibodies in the treatment
of AIHA should explore autoantibody IgG subclass
switching and alterations in complement inhibitory pro-
teins on red blood cell membranes as potential correlates
of hematologic response.Consent
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